Press releases, workshop summaries, and editorials
Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease
Shared platform to catalyze research collaboration toward biomarker discovery to advance the development disease therapies
The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective therapies for the disease. The portal enables researchers to study complex data sets and perform genome-wide analyses at a scale previously impossible.
Accelerating Research for Parkinson’s Disease
The Accelerating Medicines Partnership Parkinson's disease (AMP PD) program, launched on Jan 30, 2018, is the most ambitious initiative so far to find a cure for Parkinson's disease. Formed by the US National Institutes of Health (NIH), the US Food and Drug Administration (FDA), five biopharmaceutical and life science companies, and the Michael J. Fox Foundation, this partnership is focused on discovering novel therapeutic targets and on developing biomarkers to help validate existing therapeutic targets for Parkinson's disease.